Rejected at 12:19 a.m. Jan, 15, 2025 ] by Cameron
Author: knight
Related Note: 1495820453446
Rationale for change

Pg 438 of FA2024 there is a table it shows ET as well no reason to have MF w/o ET..

Rejection reason

Need more specific source, provided source is regarding JAK2 mutation and not indications for Ruxolitinib (new clozes typically require QBank sourcing shown it is tested)

Text Text
Extra
Because these target the proliferation of myeloid cells, myelosuppression is a side effect
Lecture Notes
Empty field
Missed Questions
Empty field
Pathoma
Empty field
Boards and Beyond
Empty field
First Aid
Sketchy
Watch Myeloproliferative Neoplasms & Myelodysplastic Syndromes
Sketchy 2




Watch Bone Marrow Failure DDx
Sketchy Extra
Empty field
Picmonic
Empty field
Pixorize
Empty field
Physeo
Empty field
Bootcamp
Watch associated Bootcamp video - Plasma Cell Dyscrasias and Myeloproliferative Disease: Polycythemia Vera and Essential Thrombocythemia
OME

Additional Resources
Empty field
One by one
Empty field
#AK_Original_Decks::Step_1::Zanki_Pharmacology #AK_Step1_v12::#AMBOSS::rB0fXi #AK_Step1_v12::#AMBOSS::4ma3fO #AK_Step2_v12::#SketchyIM::08_Hematology_&_Oncology::05_Bone_Marrow_Failure::01_Bone_Marrow_Failure_DDx #AK_Step2_v12::#AMBOSS::bF0Hg3 #AK_Step1_v12::#AMBOSS::CnaqvO #AK_Step1_v12::#UWorld::Step::8540 #AK_Step2_v12::#AMBOSS::ZF0Zg3 #AK_Step1_v12::#Physeo::11_Pathology::10_HemeOnc_Pathology::14_Myeloproliferative_Disorders #AK_Step1_v12::^Other::^HighYield::2-RelativelyHighYield #AK_Step2_v12::#B&B::07_Hematology_and_Oncology::03_White_Cells::02_Myeloproliferative_Disorders #AK_Step1_v12::#SketchyPharm::08_Antineoplastics::SmallMoleculeInhibitors(TyrosineKinase_ProteasomeInhibitors_CDKInhibitors) #AK_Step2_v12::#AMBOSS::zt0rT3 #AK_Step1_v12::#FirstAid::10_Hematology_and_Oncology::05_Pharm::19_Anticancer_small_molecule_inhibitors::*Ruxolitinib #AK_Step1_v12::#OME::04_Organ_Systems::05_Hematology_Oncology::04_Proliferation::02_Myeloproliferation #AK_Step1_v12::^Other::^EXPN #AK_Step1_v12::#SketchyPath::10_Myeloid_&_Lymphoid::01_Myeloid_Disorders::01_Myeloproliferative_Neoplasms_&_Myelodysplastic_Syndromes #AK_Step2_v12::#AMBOSS::-t0DT3 !AK_UpdateTags::Step1decks::Zanki-Pharmacology #AK_Step1_v12::#Bootcamp::Hematology_and_Oncology::10_Plasma_Cell_Dyscrasias_&_Myeloproliferative_Disease::03_Polycythemia_Vera_&_Essential_Thrombocythemia #AK_Step1_v12::#UWorld::COMLEX::25418 #AK_Step1_v12::#OME::Clinical::04_Organ_Systems::05_Hematology_Oncology::04_Proliferation::02_Myeloproliferation